Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.66 |
| ▸ | CDK13 | Q14004 | 6/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317706 | 1.00 | AR (1.00) | ARCRBNCDK13CDK12MAP4K1 | |
| SCHEMBL25317699 | 1.00 | AR (1.00) | ARCRBNCDK13CDK12MAP4K1 | |
| SCHEMBL25317134 | 1.00 | AR (1.00) | ARCRBNCDK13CDK12MAP4K1 | |
| SCHEMBL25317225 | 0.96 | AR (0.93) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25318479 | 0.96 | AR (0.93) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25318484 | 0.96 | AR (0.93) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25317228 | 0.96 | AR (0.93) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25316684 | 0.91 | AR (0.84) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25316941 | 0.91 | AR (0.84) | ARCRBNCDK13CDK12IRAK1 | |
| SCHEMBL25316686 | 0.91 | AR (0.84) | ARCRBNCDK13CDK12IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | AR 1/4885CRBN 945/4885CDK13 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.